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Summary
In a prospective study, long term upper-limb morbidity, perceived disabili-
ties in activities of daily life (ADL) and quality of life (QOL) were assessed
before, at one year and two years after sentinel lymph node biopsy (SLNB)
or axillary lymph node dissections (ALND) for breast cancer.
Considerable treatment related upper-limb morbidity was observed. Sig-
nificant (p<0.05) changes between before and up till two years after surgery
were found in almost all assessments of shoulder function, ADL and several
QOL subscales. Patients in the ALND group showed significant more changes
in range of motion (ROM), grip strength, arm volume, ADL and QOL physi-
cal- and role functioning, pain and sleeplessness and arm symptoms com-
pared to the SLNB group. Multivariate linear regression analysis showed that
radiation therapy on the axilla is besides ALND an important factor in the
prediction of impaired shoulder ROM and arm edema.
Introduction
The aim of modern breast cancer treatment is to obtain local tumor control,
optimal lymph node staging with minimal treatment related morbidity, good
functional result and when possible preservation of the breast. Axillary lymph
node status based on the amount of positive axillary lymph nodes in relation
to the total amount of resected lymph nodes is an important prognostic factor
in patients with breast cancer.1 Axillary lymph node dissection (ALND) still
is associated with upper limb morbidity such as pain, numbness, lymphedema,
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weakness and impaired shoulder range of motion.2 Persisting upper limb morbidity
can affect the ability to perform ADL and QOL.2,3,4
Sentinel lymph node biopsy (SLNB) was introduced for staging of the
axilla to reduce the number of unnecessary ALND’s.5 SLNB is an accurate
and safe procedure to predict metastatic disease in clinically negative axillary
lymph nodes and is more and more accepted in breast cancer treatment.5,6
The aim of the current prospective study was to analyze upper limb mor-
bidity, perceived disability in ADL and QOL till two years after SLNB or
ALND. The second aim was to analyze to which extent ALND and other
treatment variables could predict upper limb morbidity, perceived disability
and decreased QOL. At third, correlations between upper-limb morbidity and
disability in ADL and reduction in QOL were analyzed.
Materials and Methods
From June 1999 to June 2001, patients with breast carcinoma stage I or
stage II entered the study.7 Two groups of breast cancer patients participated
in the prospective study, patients who underwent conventional breast cancer
treatment with an ALND and patients who were treated according the SLNB
concept.
Sentinel lymph nodes were identified by pre-operative lymphoscintigraphy
followed by intra-operative tracing using a gamma probe and Patent blue
dye® (Blue Patenté; Labatoire Guerbet, Aulnay-sous-Bois, France). The pro-
cedure has been previously described in detail.8 Surgical and adjuvant treat-
ments were applied according to the protocol of the Comprehensive Cancer
Centre North-Netherlands (CCCN) in both groups (Table 1).
Upper limb function and ADL were assessed one day before surgery (t0)
and two years after surgery (t1). Pain was assessed with the Visual Analogue
Scale (VAS).9 Upper limb function was assessed by means of a protocollized
physical examination. Active shoulder range of motion was measured, using
a goniometer (Isomed Inclinometer; Portland, Oregon, USA) according to a
standardized protocol in forward flexion, abduction and external rotation.10
Muscle strength of shoulder abductors and elbow flexors were measured using
a handheld dynamometer (Citec®; Groningen, The Netherlands).11 For assess-
ment of the grip strength, a Yamar® hand-dynamometer (Bollingbrook, Ilinois,
USA) was used.12
Arm volume was assessed by means of surface circumference measure-
ments (at 4 cm intervals) and a mathematical formula (Sitzia’s formula) de-
rived from a formula for a frustum.13,14
ADL was assessed with the Shoulder Disability Questionnaire (SDQ) and
the Groningen Activity Restriction Scale (GARS). The SDQ is a functional
status measure that covers 16 items. It was designed to evaluate the ability to
perform daily activities in patients with shoulder disorders (shoulder related
ADLs).15 The GARS assesses the perceived restrictions (disability) in per-
forming 18 ADLs.16
Quality of Life was assessed with help of the EORTC QLQ-C30 question-
naire supplemented with the EORTC Breast Module (EORTC QLQ-BR23).17
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The core questionnaire is intended to measure general aspects of health re-
lated QOL specific to cancer patients. It incorporates five functional scales on
physical, role, cognitive, emotional and social functioning. The supplemen-
tary EORTC Breast module is a site specific module which includes four
functional scales on body image, sexual functioning, sexual enjoyment (sat-
isfaction), future perspective and four symptom scales/items including arm
symptoms, breast symptoms, systemic-therapy side effects and upsetness by
hair loss. A linear transformation to a ‘0-100’ scale of the EORTC QLQ-C30
and the QLQ-BR23 was carried out according to the EORTC Scoring Manual.18
A higher mean score for functional scales and global QOL reflects a better
level of functioning, but a higher mean score for the symptom scales/items
reflects more symptoms/problems.
Statistical analyses included descriptive statistics and t-tests for independ-
ent samples for between-group comparisons and t-tests for dependent samples
for within-group comparisons. Pearson’s χ2 test was used for dichotomous
variables. To answer the question in which extent treatment variables could
predict upper limb morbidity, perceived disability and poorer QOL, multivariate
linear regression analyses were performed. Differences were accepted as sig-
nificant if p values were <0.05. SPSS® Base 11.5 software for Windows®,SPSS
Inc., was used for statistical analysis.
Results
In the period 1999-2001, 204 consecutive patients with invasive breast
carcinoma were included in the study. After two years 181 patients could be
evaluated; 57 patients (32%) in the SLNB group and 124 patients (68%) in
the ALND group. TNM classification, receptor status and treatment charac-
teristics of these patients are presented in Table 1.
After two years substantial long-term treatment-related upper-limb mor-
bidity was observed for the whole study group. Significant changes between
before surgery and two years after surgery were found in all assessments
except strength of the elbow flexors (Table 2). ADL increased as assessed
with the SDQ (10.5; SD 29.9) and the GARS (1.8; SD 5.7) and also signifi-
cant changes were found for QOL assessed with the EORTC QLQ-C30 and
QLQ-BR23. Physical and role functions decreased. Emotional function and
symptom scales/items such as fatigue, pain, dyspnoea, constipation and finan-
cial problems increased. From the functional scales of the breast cancer module,
body image decreased (-3.2 SD 17.1) while future perspective increased (12.7
SD 28.2). Also here was an increase of side effects (4.8 SD 13.2) and arm
symptoms (8.8 SD 19.4) (Table 2)
Several changes in upper-limb function (upper-limb morbidity), ADL (per-
ceived disability) and QOL between before surgery and two years after treat-
ment were significantly different between the SLNB group and the ALND
group in favor of the first.
Multivariate linear regression analysis to predict the mean change in up-
per-limb function, ADL and QOL was performed and ALND was a signifi-
cant factor in the prediction in the majority of mean changes in the performed
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Table 1. Tumor-node-metastasis classification, receptor status and treatment 
characteristics of the patients who completed the assessments before surgery and 
two years after initial treatment 
Variable SLNB (n=57) ALND (n=124) Total (n=181) 
Patient age, years, mean (SD) 57 (11.9) 55 (11.0) 56 (11.3) 
Tumor-Node-Metastasis 
classification 
   
Stage I 44 (77%) 39 (32%) 83 (45%) 
Stage IIA 11 (19%) 66 (53%) 77 (43%) 
Stage IIB 2 (4%) 19 (15%) 21 (12%) 
Estrogen-receptor status    
Positive 35 (61%) 89 (72%) 124 (68%) 
Negative 22 (39%) 35 (28%) 57 (32%) 
Surgical treatment of breast    
Mastectomy 17 (30%) 57 (46%) 74 (40%) 
Lumpectomy 40 (70%) 67 (54%) 107 (60%) 
Adjuvant therapies*    
Radiotherapy of breast 37 (65%) 79 (64%) 116 (64%) 
Radiotherapy of axilla 0   (0 %) 14 (11%) 14 (8%) 
Chemotherapy 9 (16%) 51 (41%) 60 (33%) 
Hormonal therapy 10 (18%) 64 (52%) 74 (41%) 
Table 1. Tumor-node-metastasis classification, receptor status and treatment 
characteristics of the patients who completed the assessments before surgery and 
two years after initial treatment 
Variable SLNB (n=57) ALND (n=124) Total (n=181) 
Patient age, years, mean (SD) 57 (11.9) 55 (11.0) 56 (11.3) 
Tumor-Node-Metastasis 
classification 
   
Stage I 44 (77%) 39 (32%) 83 (45%) 
Stage IIA 11 (19%) 66 (53%) 77 (43%) 
Stage IIB 2 (4%) 19 (15%) 21 (12%) 
Estrogen-receptor status    
Positive 35 (61%) 89 (72%) 124 (68%) 
Negative 22 (39%) 35 (28%) 57 (32%) 
Surgical treatment of breast    
Mastectomy 17 (30%) 57 (46%) 74 (40%) 
Lumpectomy 40 (70%) 67 (54%) 107 (60%) 
Adjuvant therapies*    
Radiotherapy of breast 37 (65%) 79 (64%) 116 (64%) 
Radiotherapy of axilla 0   (0 %) 14 (11%) 14 (8%) 
Chemotherapy 9 (16%) 51 (41%) 60 (33%) 
Hormonal therapy 10 (18%) 64 (52%) 74 (41%) 
581Seoul, Korea, June 10-14, 2007
assessments of upper-limb function, ADL and QOL. Radiation of the axilla
was significant in forward flexion, abduction, abduction/external rotation and
arm volume. Mastectomy was a predictor for the SDQ, QOL scales/items
social functioning, appetite loss and body image and breast symptoms.
Conclusions
This study showed significant long-term upper limb morbidity, associated
ADL disability and also decreased QOL in breast cancer patients undergoing
SLNB and/or ALND two years after treatment. Patients undergoing SLNB
had significantly less long-term upper limb morbidity, ADL disabilities and
declination of some items of QOL two years after treatment compared to
patients undergoing ALND. In the assessment of changes in upper limb func-
tion, ADL and QOL, ALND is the most frequent found predictor of deterio-
ration. Additional radiation on the axilla predicts a further decrease in shoul-
der ROM and arm edema.
Significant differences between the groups concerned numbness, shoulder
ROM in abduction, abduction/external rotation, grip strength and arm vol-
ume. Decrease in upper limb function in the SLNB group was only significant
for ROM in abduction/external rotation, strength shoulder-abductors and grip
strength. The perceived disabilities in ADL assessed in this study with the
SDQ and GARS are significant but relatively mild. The difference in mean
change of ADL between pre surgery and two years after surgery comparing
SLNB and ALND is significant using the GARS but not for the SDQ. Con-
cerning QOL for the entire study group a significant decrease was found over
the two years for physical and role functioning and body image whereas
emotional functioning and future perspective showed significant increase over
this period (Table 2). The improvement of emotional functioning and future
perspective can be explained by the fact that the first assessment took place
one day before surgery. Obviously at this time patients were nervous and
stressed and also uncertain about their future perspective.21 Two years later
these aspects were highly improved.
All significant changes over the two years after treatment in the SLNB
group are for the better and the significant changes over the two years after
treatment in the ALND group are for the worse except emotional functioning
and future perspective. Nevertheless the interpretation of the scores on the
EORTC QLQ-C30 and QLQ-BR23 in relation to clinical relevance needs
some discussion. All the statistically significant differences found in our study
within and between the groups could be interpretated as relatively small clini-
cally important differences except the improvement of emotional functioning
which could be interpretated as a very large clinically important difference.
References
1. Donegan WL. Prognostic factors: Stage and receptor status in breast cancer. Cancer
1992;70:1755-64.
2. Rietman JS, Dijkstra PU, Hoekstra HJ, Eisma WH, Szabo BG, Groothoff JW, et
582 ISPRM – 4th World Congress
al. Late morbidity after treatment of breast cancer in relation to daily activities and
quality of life; a systematic review. Eur J Surg Oncol 2003;29(3):229-38.
3. Poole K, Fallowfield LJ. The psychological impact of post-operative arm morbid-
ity following axillary surgery for breast cancer: a critical review. The Breast
2002;11:81-7.
4. Rietman JS, Dijkstra PU, Debreczeni R, Geertzen JHB, Robinson DPH, Vries de
J. Impairments, disabilities and health related quality of life after treatment for
breast cancer: a follow-up study 2.7 years after surgery. Disabil Rehab 2004;26(2):78-
84.
5. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL, et al.
Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann
Surg 1995;222(3):394-9.
6. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al.
Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically
negative lymphnodes. Lancet 1997;349(9069):1864-7.
7. International Union Against Cancer. Breast Tumors. In: Sobin LH, Wittekind Ch.,
eds. TNM Classification of malignant tumors. 6th ed. New York: Wiley-Liss, 2002,
131-142.
8. Rutgers EJ, Jansen L, Nieweg OE, de Vries J, Schraffordt Koops H, Kroon BB.
Technique of sentinel node biopsy in breast cancer. Eur J Surg Oncol 1998;24(4):316-
9.
9. Gerber L, Lampert M, Wood C, Duncan M, D’Angelo T, Schain W, et al. Com-
parison of pain, motion and edema after modified radical mastectomy vs. local
excision with axillary dissection and radiation. Br Canc Res Treatm 1992;21(2):139-
45.
10. Green S, Buchbinder R, Forbes A, Bellamy N. A standardized protocol for meas-
urement of range of movement of the shoulder using the Plurimeter-V inclinom-
eter and assessment of its intrarater and interrater reliability. Arthritis Care Res
1998;11(1):43-52.
11. Ploeg RJO van der, Fidler V, Oosterhuis HJGH. Hand-held myometry: reference
values. J Neurol Neurosurg Psych 1991;54:244-7.
12. Mathiowetz V, Weber K,Volland G, Kashman N. Reliability and validity of grip
and pinch strength evaluations. J Hand Surg 1984;9(2):222-6.
13. Sitzia J. Volume Measurement in Lymphedema Treatment: examination of formu-
lae. Eur. J. Canc Care 1995;4(1):11-6.
14. Meijer RS, Rietman JS, Geertzen JHB, Bosmans C, Dijkstra PU. Validity and
intra- and interobserver reliability of an indirect volume determination of patients
with edema of the upper extremity. Lymphology 2004;37(3):127-34.
15. Heijden GJ van der, Leffers P, Bouter LM. Shoulder disability questionnaire
design and responsiveness of a functional status measure. J Clin Epidemiol
2000;53(1):29-38.
16. Kempen GI, Miedema I, Ormel J, Molenaar W. The assessment of disability with
the Groningen Activity Restriction Scale. Conceptual framework and psychomet-
ric properties. Soc Sci Med 1996;43:1601-10.
17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The
European Organisation for Research and Treatment of Cancer QLQ-C30: a qual-
ity-of-life instrument for use in international clinical trials in oncology. J Natl
Cancer Inst 1993;85(5):365-76.
18. Fayers P, Aaronson NK, Bjordal K, Sullivan M. EORTC QLQ-C30 scoring manual.
Brussels: EORTC Publications 1997.
